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Prostate cancer is the second most commonly diagnosed cancer in American men over the age of 45 years and is
the third most common cause of cancer related deaths in American men. In 2012 it is estimated that 241,740 men
will be diagnosed with prostate cancer and 28,170 men will succumb to prostate cancer. Currently, radiation
therapy is one of the most common definitive treatment options for localized prostate cancer. However, significant
number of patients undergoing radiation therapy will develop locally persistent/recurrent tumours. The varying
response rates to radiation may be due to 1) tumor microenvironment, 2) tumor stage/grade, 3) modality used to
deliver radiation, and 4) dose of radiation. Higher doses of radiation has not always proved to be effective and have
been associated with increased morbidity. Compounds designed to enhance the killing effects of radiation,
radiosensitizers, have been extensively investigated over the past decade. The development of radiosensitizing
agents could improve survival, improve quality of life and reduce costs, thus benefiting both patients and
healthcare systems. Herin, we shall review the role and mechanisms of various agents that can sensitize tumours,
specifically prostate cancer.Review
Introduction
In 2012 it is estimated that 241,740 men will be diagnosed
with prostate cancer and 28,170 men will succumb to
prostate cancer [1]. The lifetime risk of being diagnosed
with prostate cancer is 1 in 6 [2]. Prostate cancer is the
second most commonly diagnosed cancer in American
men over the age of 45 years and is the third most com-
mon cause of cancer related deaths in American men
[1,3]. The majority of men with newly diagnosed localized
prostate cancer may be eligible for active surveillance,
surgery (prostatectomy or cryoablation), or radiation the-
rapy (external beam or brachytherapy) either alone or in
combination with androgen deprivation therapy. This
review will focus on radiation therapy, which is a common
treatment option for localized prostate cancer. Radiation
therapies, external beam, proton beam, and interstitial
brachytherapy, are becoming increasingly in demand by
patients [4,5] as a means to avoid major surgery and the
side effects and convalescence associated with surgery [6].* Correspondence: Charles.rosser@orlandohealth.com
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reproduction in any medium, provided the orRadiation therapy in prostate cancer is by no means
innocuous and is associated with urinary and bowel side
effects. Furthermore, it has been reported that based on
the clinical presentation of the cancer, only 33-66% of
patients undergoing radiation therapy are disease-free
five years after the initial procedure, this includes more
contemporary series addressing dose escalation (i.e., ≥78
Gy) [7-12]. The varying response rates to radiation may
be due to 1) modality used to deliver radiation, 2) dose
of radiation, 3) tumor stage/grade, 4) confounding me-
dical co-morbidities and 4) intrinsic microenvironment
of the tumor. Herein, we will discuss the intrinsic micro-
environment of tumors and how radiosensitizing agents
(i.e., drugs that can enhance the effectiveness of ra-
diation, kill to the target tissue) may be used to improve
the efficacy of radiation therapy [13].
Cellular effects of ionizing radiation
To understand the mechanism and role of various radio-
sensitizing agents, it is important to review briefly the
cellular response to radiation. Radiation is clinically admi-
nistered either by an external source, linear accelerator,
directed toward the tumor or an internal source, radio-
active decay from within the tumor [13]. Five mechanisms
have been described to explain the way radiation interactsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tric effect, the Compton effect, the pair production, and
the photodisintegration [14]. However, the Compton ef-
fect is widely viewed as the mode of interaction most rele-
vant for the range of energies used in clinical radiation
therapy. In the Compton effect, the observed biologic
effect results from photons creating multiple ionizations
by ejection of electrons from the target biomolecule [15].
In this regard, the extent of biologic effects in cells after
exposure to ionized radiation is largely due to oxygen with
the subsequent production of free radicals. These free
radicals can break chemical bonds present in critical cell
structures and molecules, namely cellular DNA.
DNA is by far the critical target for the biologic effects
of radiation. Cell death is strongly associated with the ex-
tent of DNA damage [16,17] with radiosensitivity being
more pronounced in cells that cannot effectively repair
DNA damage [18-20]. Furthermore, cell death occurs at a
higher rate when radiation is focused on the nucleus as
opposed to the cytoplasm [21-23]. Disruption of DNA
takes place via both direct and indirect effect of radiation.
Taking into account the size of the cell and the small
amount of DNA in the cell, most of the damage occurs in-
directly [24]. This means that the photons of radiation are
less likely to directly damage the DNA, but more likely to
ionize surrounding molecules, which subsequently
destabilize nucleic acids [25]. The mechanism behind oxy-
gen radiosensitizing is related to this process of indirect
damage (Figure 1). The presence of oxygen in irradiated
tissues prevents repair of free radical-induced damage by
forming irreversible peroxides in the fractured molecules.
This process is sometimes called “fixing” the radiation [26].
Many types of damage to DNA molecules, dimers,
adducts, oxidative base damage, intra- and intercross-links,
DNA-protein cross-links, single- and double-strand breaks
can be detected after radiation exposure.Figure 1 Cellular Effects of Ionizing Radiation. Photons of radiation pro
where photons eject electrons from target biomolecules in the cytoplasm,
producing free radicals, which break DNA.According to the Compton effect, multiple ionizations
are created and this leads to multiple free radical forma-
tion [13,15]. It is believed that these radicals are pro-
duced in clusters and in discrete areas. Thus, it is
thought that the multiple broken bonds and subsequent
nucleic acids damage are likely to be clustered as well.
Often, the term “locally multiply damaged site” is used
to refer to this phenomenon [27]. It has been suggested
that clustered DNA damage is critical to clinically sig-
nificant effects [27,28]. These effects truly depend on the
cellular response following a radiation insult, including
the ability to repair DNA damage and to activate sur-
vival mechanisms.
Cellular detection of DNA damage
Shortly after exposure to ionizing radiation, a signal is
transmitted to the regulators of the cell cycle machinery
and the sensors of DNA damage. Cells with damaged
DNA undergo G2/M cell cycle arrest (Figure 2). During
this cell cycle arrest, the cells can either 1) repair and
proceed through the cell cycle, 2) not repair and stay
arrested, or 3) not repair and undergo apoptosis [29].
Cells under hypoxic conditions (i.e., unable to generate
free radicals) show much less sensitivity to radiation as
opposed to well oxygenated cells [30]. It then becomes
intuitive that radiation effects are directly related with blood
flow and oxygen concentration of the target tissue [31].
Several mechanisms have been proposed for the cascade
leading to the cellular recognition of a radiation insult.
Rad17-RFC, 9-1-1, and MRN complexes are three families
of proteins that have been implicated in the initial sensing
of DNA damage [32-35]. The Rad17-RFC complex is
composed of the protein Rad17 and four subunits of repli-
cation factor C (Rfc2, Rfc3, Rfc4, Rfc5) [33]. The 9-1-1
complex consists of proteins Rad9, Rad1, and Hus1 [34].
This complex is thought to be more involved in single-duce direct DNA damage, but it is less likely than indirect damage,
creating multiple ionizations, especially in oxygen compounds and
Figure 2 G2/M Arrest after Ionizing Radiation DNA Damage. Activation of ATM and ATR by DNA damage produces G2 arrest. Once DNA is
repaired Cdc25c is inactivated which stimulates Cdc2 and enhances cell entry into mitosis by Cyclin B.
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proteins Mre11, Rad50, and Nbs1, and it is thought to be
more specific to double-strand DNA damage and homolo-
gous repair [35,37]. These complexes are able to dock on
fractured DNA or near the site of damaged DNA and
transmit signals downstream to the transducers, which are
members of the phosphoinositide 3-kinaserelated kinase
such as ATM (ataxia-telangiectesia mutated protein) and
ATR [32].
While ATM and ATR have some overlapping activities,
they are activated by separate signals and by different
types of DNA damage [38,39]. In this regard, ATM is
more the central orchestrator of the cascade. In addition,
some evidence implicates ATM/ATR as being involved in
the initial sensing of DNA damage [40,41]. When ATM
and ATR are activated, they relay the signal to various
downstream effectors that mediate cell cycle arrest, DNA
repair, and apoptosis. The specific effectors will be dis-
cussed according to the cellular response.Cell cycle arrest
Progression through the cell cycle is carefully coordi-
nated by a series of events that culminate in DNA syn-
thesis and cellular division. The control of multiplication
relies on accelerating and braking mechanisms, which
act on driving the cell cycle leading to mitosis. There are
many checkpoints throughout the cell cycle that can
prevent important cycle transitions until the integrity of
the DNA is ensured [42-45]. Cells respond to ionizing
radiation is variable, depending on when the cell is
exposed to radiation in its cell cycle. Cells are extremely
sensitive to radiation during mitosis in which there is no
DNA repair [46-49].DNA damage can activate multiple pathways that
eventually lead to G1 arrest. When ATM is activated, it
transduces signals to some key effector molecules. ATM
stabilizes p53 by phosphorylating its serine-15, whereas
it also adds a phosphate group on serine 395 of MDM2
[50]. In this context, phosphorylation of MDM2 prevents
p53-MDM2 nuclear export and degradation of p53
[32,50]. ATM is also known to phosphorylate Chk2,
which subsequently phosphorylates p53 on serine 20
[51]. This extra phosphorylation further prevents inter-
action of p53 and MDM2. At this point, the net result is
more available nuclear p53, which is free to activate p21,
a major inhibitor of the cyclin E-CDK2 complex [52].
This inhibited complex is important for G1 transition
because it normally phosphorylates pRb and leads to the
subsequent release of E2F [53,54]. ATM is also the co-
ordinator of a p53/p21 independent G1 arrest pathway.
When ATM activates Chk2, this kinase phosphorylates
cdc25A, which is primed for ubiquination and subse-
quent degradation [55]. This is significant because
cdc25A is a phosphatase that removes inhibitory phos-
phates from CDK2 and CDK4, which both are important
for G1 phase progression molecules [32]. During the G1
phase, irradiated cells have been shown to be radio-
resistant, but their radiosensitivity increases at the end
of this phase [56,57].
The most radioresistant phase of the cell cycle is the S
phase, when cellular DNA is replicating [58,59]. During
this phase, numerous nuclear machineries are available to
repair and confirm the integrity of the DNA. However, if
double-strand DNA damage occurs it can retard the repli-
cation of DNA and thus halt further DNA synthesis. ATM
is again the key protein involved in this checkpoint
[60,61]. The main pathway involves facilitating the
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activity is crucial for the function of cyclin E/A-CDK2 com-
plexes, which oversee progression through the S-phase.
Finally and most commonly, irradiated cells can be
blocked in the G2/M phase, which post mitosis is the
next most sensitive phase in the cell cycle. Multiple
pathways are involved for this arrest, and the complete
details are not yet known [32]. However, the final step in
this pathway is deactivation of the cyclin B-CDK1 com-
plex, which orchestrates the G2/M transition [62,63]. As
with the pathways discussed above, activation or deactiva-
tion of the CDK1 complex is determined by the specific
site of phosphorylation. The ATM/CDC25A pathway is
also important here because cdc25A is an activator of
cyclin B-CDK1 complex [64]. Through p53, ATM acti-
vates p21, which is an inhibitor of an activator of CDK1,
namely CAK (CDK activating kinase) [61].DNA repair
As described above, irradiated cells sense DNA damage,
which eventually activates the mechanism for DNA re-
pair. Various repair processes are activated according to
the lesion types, with double-strand breaks being the most
lethal lesion to the cell as opposed to single-strand breaks
[65]. Repair of these lesions can be done either through
homologous recombination (HR) or non-homologous
end-joining (NHEJ) [66]. In the former, either the intact
chromosome or the sister chromatid serve as a template
to reconstruct the missing DNA. HR is most effective in
late S or G2 phase, when the sister chromatids have repli-
cated but still attached [65]. NHEJ is more important in
G1 and early S phase, but it essentially occurs throughout
the cell cycle [66].
Following exposure to ionizing radiation, histone H2AX
becomes phosphorylated via the ATM protein [67,68],
resulting in a sharp accumulation of 53BP1 protein. This
protein is involved in phosphorylating the tumor suppres-
sor molecule p53, activating proteins essential for DNA
repair, and inducing G2 checkpoint block [69-71]. Thus,
G2 checkpoint induced by radiation, possibly via 53BP1,
have more allocated time for repair and to escape death.
G1 phase arrest also allocates more time for repair of
DNA damage sustained prior to DNA synthesis.
The interval between delivered doses of radiation is
very critical in the ability to effectively prevent target
cells from DNA repair. It has been shown that the ability
of the cell to repair DNA damage is inversely related to
the dose of radiation [13]. Two doses separated in time
are less cytotoxic than the sum of the two doses given at
a single time, thus the benefit of hypofractionation. In
addition, the more closely the two doses are applied in
time, the more the resulting effects are similar to those
of a large single dose. Thus, sublethal radiation tends tocause minimal DNA damage, which is then more likely
to be repaired successfully [13,72,73].
Cell death
The ultimate desired response of a cell to clinical ioni-
zing radiation is cell death. DNA repair and cell survival
are possible if the cell is exposed only to sublethal radi-
ation dose with minimal alterations. If the limits of rep-
arative response are exceeded, the damage is irreversible
and the net result is cell death [74]. Radiation damage
can activate signaling cascades that lead to programmed
cell death or apoptosis [13,74]. The irradiated cell can
exit permanently the cell cycle and undergo terminal dif-
ferentiation. In this terminal pathway, the cell can no
longer cycle and proliferate [75-77]. In other cases, the
DNA damaged cell can die as it attempts to undergo mi-
tosis, a process known as “mitotic catastrophe” [75].
Radiation-associated prostate cancer cell gene expression
In prostate cancer cells, molecular events leading to the
changes in cell cycle progression and cell survival are
altered following exposure to ionizing radiation. For ex-
ample, it has been shown that expression of key proteins
associated with proliferation, Ki-67, and apoptosis, Bcl-2
and Bax, are dramatically altered in prostate cancer
tumors following radiotherapy [78-80]. Compared to pre-
treatment tumors, locally recurrent prostate cancers after
radiation treatment were associated with overexpression
of p53 and Bcl-2 [79,81-86]. Furthermore, the overexpres-
sion of these proteins may lead to radiotherapy failure,
suggesting these cellular proteins may play a part in the
cellular process conferring radiation resistance.
Radiosensitizers in prostate cancer
Understanding how cancer cells respond to ionizing ra-
diation has enhanced the understanding of the molecular
basis of radiation resistance. This in turn has led to break-
throughs in the development of strategies for increasing
radiosensitivity, as well as improving the therapeutic index
of radiation therapy in prostate cancer patients.
Radiation sensitization targets
Below is a brief review of radiation sensitization targets
of interest in prostate cancer and some of the preclinical
data associated with targeting these molecules (Table 1).
p53/MDM2
p53 expression and function in tumor cell has an import-
ant role in the cellular response to DNA damage, facilitat-
ing cell cycle arrest, and death [87]. While overexpression
of p53 is associated with local recurrence of prostate can-
cer post-radiation, p53 gene transfer has been studied as
an option to increase radiosensitivity [88]. It has been
shown that combining ionizing radiation and adenoviral
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DU145 (p53-mutated) and PC-3 (p53-null) to be more
radiosensitive [89]. Furthermore, with combination the-
rapy, the number of apoptotic cells increased 7-fold in
DU145 cells and 2-fold in PC-3 cells [89]. Radiosensitiza-
tion of prostate cancer cells with adenoviral p53 gene
therapy was independent of the status of p53, as the
sensitization is seen in both the p53 (wild-type) human
prostate cancer cell LNCaP and p53 (null) PC-3 lines [90].
In addition, in vivo adenovirus-mediated p53 gene therapy
acts synergistically with ionizing radiation to reduce
LNCaP xenograft tumor growth [91].
Mk-1775, a Wee1 kinase inhibitor has been reported to
radiosensitized p53-defective human tumor cells, includ-
ing PC-3 prostate cancer cells. The inhibition of Wee1
kinase produce abrogation of G2 checkpoint and as p53-
defective cells cannot proceed through G1 checkpoint for
repair and thus they pass directly to mitosis with DNA
lesions, causing mitotic death, not apoptosis [92]. Poly
(ADP-ribose) polymerase-1 (PARP1) is essential for DNATable 1 Radiation sensitization targets
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cycle regulation and the response of cells to ionizing
radiation. MDM2 is overexpressed in many tumors in-
cluding prostate cancer, and it is associated with radiation
resistance. It has been shown that antisense oligonucleo-
tides that target MDM2 can render prostate cancer cells
more vulnerable to ionizing radiation independent of the
p53 status, both in vitro and in vivo [97-99]. The MDM2
antisense oligonucleotide increased radiation-induced in-
hibitory effects on tumor growth in SCID or nude mice
with LNCaP, PC3, as well as other xenografts [99].PTEN/Akt
The PTEN gene codes for a phosphatase in the phosphati-
dylinositol 3'-kinase (PI3'K)-mediated signal transduction
pathway. PTEN can block pathways of proliferation and
can induce apoptosis via the suppression of Akt, a serine-
threonine kinase [100]. PTEN gene therapy in PC-3 cells
(PTEN deleted, up-regulation of phosphorylated Akt) led
to a significant decrease in cellular growth [101]. It has
been further demonstrated that transfection of LNCaP
prostate cells with the PTEN gene resulted in Bcl-2 down-
regulation [102]. Given that Bcl-2 is associated with
prostate cancer cell radiation resistance [103-105] and that
PTEN has tumor suppressor properties, PTEN gene ther-
apy has been studied as a radiosensitizer. In fact, forced
expression of PTEN in prostate cancer cells sensitizes cells
to radiation and downregulated Bcl-2 expression in two
prostate cancer cell lines that over express Bcl-2, PC-
3-Bcl-2 and LNCaP. Furthermore, forced overexpression
of PTEN in these prostate cancer cells potentiated a
G2/M cell cycle arrest. These effects were not evident in
prostate cancer cells that did not overexpress Bcl-2 [106].Bax/Bcl2
Stable transfection of Bcl-2 into PC-3 prostate cancer cell
line rendered these cells more radiation resistant than the
parent PC-3 cells [107]. In this regard, the anti-apoptotic
gene Bcl-2 is associated with resistance to radiation, or at
least is associated with delay of radiation-induced apop-
tosis in human prostate cancer cells [107]. Studies have
focused on re-establishing a balance between the Bcl-2
family members in achieving radiosensitization. For
example, some studies focused on selective overexpression
of the pro-apoptotic gene Bax directed. Regardless of the
levels of Bcl-2 protein, Bax gene therapy led to
programmed-cell death [108]. Furthermore, PAR-4, an-
other pro-apoptotic protein, is a potent modulator of NF
kappa β activity and Bcl-2 protein expression. It has been
found that forced over-expression of PAR-4 increases
radiosensitivity in human prostate cancer cells [105].
Furthermore, Oblimersen, a phosphorothioate antisense
oligonucleotide complimentary to the Bcl-2 mRNA, hasbeing used as an inhibitor of Bcl-2 expression to enhance
the therapeutic effect of radiation therapy [106].COX-2
Cyclooxygenase-2 (COX-2) is involved in many pro-
cesses such as inflammation, proliferation, angiogenesis,
carcinogenesis, and apoptosis. When overexpressed in
cancer, it is associated with more aggressive biologic be-
havior and poor prognosis [109]. It has been reported
that TNF-induced cell death and CD95-triggered apop-
tosis are enhanced by selective COX-2 inhibitors in
previously apoptotic resistant cell lines [110]. COX-2 is
constitutively expressed in both androgen-responsive
LNCaP and androgen-nonresponsive PC-3 cells. The
apoptotic activity of the COX-2 inhibitor, celecoxib, was
studied in these prostate cancer cells. Celecoxib induces
apoptosis in both cell lines. However, normal human
prostate epithelial cells have low levels of COX-2, and
thus do not undergo apoptosis with celecoxib [111]. In
addition, celecoxib sensitized PC-3, DU145, and LNCaP
prostate cancer cells to the killing effects of radiation
[112]. Currently there is also in vivo evidence showing
that celecoxib enhances tumor response to radiation in
A431 human tumor xenografts in nude mice [113-115].
Thus with expression of COX-2 associated with radiation
resistance and tumor aggressiveness, reduction of COX-2
expression noted to sensitize cells to radiation.Others
ATM is another key protein, discussed earlier, which is
central in coordinating the cellular response to ionizing
radiation. When PC-3 (p53-mutant) cells become infected
with adenoviral vectors expressing antisense ATM RNA,
their sensitivity to ionizing radiation was enhanced [116].
Other researchers are looking at transfecting adeno-
viruses that selectively replicate in prostate tumor cells
[117]. The oncolytic adenovirus CG7870 has tumor-
specific promoters driving the expression of E1A and
E1B proteins. In vitro, combination of the adenovirus
and radiation are synergistic at lower doses of radiation.
In vivo, combination of CG7870 with radiation therapy
significantly increased antitumor efficacy compared to
either therapy alone [117]. Similarly in vitro and in vivo
radiation sensitizing results were evident with the onco-
lytic adenovirus CV706 [118]. Another known aggressive
phenotype of human prostate cancer is the overexpres-
sion of vascular endothelial growth factor (VEGF) and
its cognate soluble receptor KDR [119]. The soluble
receptor binds to VEGF and prevents its binding to
its cellular receptor, while sKDR gene delivery to prostate
cancer cells increased their sensitivity to ionizing radiation
[120]. Furthermore, caspase-1 is a key protein involving
the apoptotic pathway in prostate cancer cells [121].
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ionizing radiation [122].
The type 1 insulin-like growth factor receptor (IGF-1R)
has been reported to be up-regulated in prostate cancer
[123] and is speculated to play a role in cellular prolifera-
tion, cell cycle progression, and resistance to apoptosis
[124]. Recently, the siRNA depletion of IGF-1R in DU145
and PC-3 cells has shown to enhanced sensitivity to ra-
diation and as well as to DNA-damaging agents by inhibit-
ing DNA double strand break repair [125,126], supporting
the use of IGF-1R inhibitors with radiation therapy.
The A Disintegrin and Metalloprotease (ADAM) genes
have been reported to play a role in cellular behavior
[127], in particular prostate carcinogenesis [128-130]. In-
hibition of ADAM9 in C4-2 androgen independent
metastatic human prostate cancer cells by siRNA knock-
down resulted in increase E-cadherin and integrins lead-
ing to sensitization to radiation and chemotherapy [131].
Signal transduction is involved in almost every import-
ant signaling pathway for cellular processes including
the pathways for radiation resistance. Some molecular
targets have therefore been identified for enhancing radi-
ation effects. In one study, the radiosensitizing potential
of a ribonucleotide reductase inhibitor, named Didox (DX;
3,4-Dihydroxybenzohydroxamic acid) was investigated in
PC-3 cells. DX showed a significant radiosensitizing effect
in p53 null prostate cancer cells by overcoming radiation
induced NF kappa-β activity and Bcl-2 expression [132].
In many cancers, the proliferative phenotype is derived
from enhanced activation of Ras, which is a critical protein
whose overactivity is also associated with radiation resis-
tance. In this context, blocking Ras activation with farne-
syltransferase inhibitors enhanced radiosensitization of
tumor cells that expressed activated Ras, in both in vitro
studies and in xenograft models [133]. When treating
prostate cancer cells with farnesyltransferase inhibitors,
there was a reduction in the clonogenic survival of pros-
tate cancer cells expressing oncogenic H-ras after irradi-
ation [134].
Another way of enhancing radiosensitivity is through
inhibition of deacetylase inhibition. The histone deacety-
lase (HDAC) inhibitor suberoylanilide hydroxamic acid
has broad range antitumor properties [135]. Combining
suberoylanilide hydroxamic acid with exposure to ioniz-
ing radiation was found to enhance radiation-induced
apoptosis in DU145 [136]. Thus, the blocking of signal
transduction involved in cell survival pathways is a cru-
cial strategy for the development of radiosensitizers.
Intraprostate neuroendocrine cells have been reported
to participate in prostate cancer development, progres-
sion, and resistance to conventional therapy. One neuro-
peptide secreted by neuroendocrine cells is neurotensin,
a ligand with a high affinity to neurotensin receptor 1
(NTR1), a receptor with known stimulatory activity inseveral human neoplastic tissues [137-139]. NTR1 is
expressed in aggressive prostate cancer cells but not in
normal prostate cells [140]. NTR1 enhances DNA synthe-
sis, cell proliferation, and survival by increasing the ex-
pression of mitogen-activated protein kinase (MAPK),
phosphoinositide-3-kinase (PI3K) activation and epider-
mal growth factor receptor (EGFR) [141]. In vitro and
in vivo studies of irradiation and SR48692, a NTR1 selec-
tive receptor antagonist, have demonstrated a reduction in
EGFR phosphorylation leading to increased rates of apop-
tosis and reduction in xenograft tumor burden [142].
Naturally compounds with potential radiation
sensitization
Prostate cancer cells with the capacity for a more efficient
repair, with a more robust cell cycle checkpoint activation
and with decrease rates of apoptosis are better prepared to
overcome the killing effects of radiation. Many natural
compounds have been studied and reported to have sig-
nificant antiproliferative and antitumorigenic effects on
prostate cancer cells. There is also a trend to identify those
that can potentiate the sensitivity of the cancer cells to ra-
diation. Genistein, a naturally occurring isoflavonoid, has
been reported to have potent antiproliferative effects on
prostate cancer cells both in vitro and in vivo [143-146]. It
is reported that genistein combined with radiation causes
a significantly greater inhibition of primary tumor growth
compared with genistein or radiation alone. The genistein
combined with radiation is associated with a decrease in
number of metastatic lymph nodes in a prostate cancer
orthotopic model [146]. In DU145 cells, radiosensitivity
was enhanced with even low concentrations of genistein
[147]. Resveratrol (RSV), a natural polyphenol compound,
was shown to enhance prostate cancer cell response to ir-
radiation by 1) inhibiting activation of Akt, 2) enhancing
activation of ATM and AMPK pathways, and 3) effecting
pathways encompassing p53, p21, and p27, which are
associated with early cell cycle arrest. Perturbation of these
molecules result in an increase in radiation induced DNA
damage and apoptosis [148]. DAB2IP is a member of
GTPase-activating protein family inhibiting the Ras-
mediated signal pathway and is often downregulated in
prostate cancer, i.e., a potential tumor suppressor gene
[149]. Loss of DAB2IP expression in prostate epithelia
may lead to epithelial mesenchymal transition, which has
a key role in the development of metastatic disease [150].
The loss of DAB2IP gene expression in prostate cancer
cells produces an efficient DNA double-strand break re-
pair, less cell cycle arrest and the development radiation
resistance cells. Treatment with a Ras signaling pathway
inhibitor, FTI-277, resulted in radiosensization of DAB2IP
deficient PC-3 prostate cancer cells [151].
Defects in the apoptosis machinery have been linked
to tumors being resistance to current therapeutic
Table 2 Accruing clinical trials combining radiosensitizing agents with radiation therapy
Trial description Sponsor Status
Sunitinib with hormonal ablation in patients with localized prostate
cancer
MD Anderson Cancer Center Ongoing, not
recruiting
SU5416 with hormonal ablation in patients with localized prostate cancer University of Chicago Unknown
Everolimus with hormonal ablation in patients with high risk localized
prostate cancer
University of Michigan Not yet open
TAK-700 with hormonal ablation in patients with high risk localized
prostate cancer
Radiation Therapy Oncology Group Recruiting
Everolimus with hormonal ablation in patients with high risk locally
advanced prostate cancer
Centre Val d’Aurelle – Paul Lamarque Recruiting
Bevacizumab with hormonal ablation in patients with high risk localized
prostate cancer
Benaroya Research Institute Completed
Everolimus for salvage treatment of biochemical recurrence after
prostatectomy
Abramson Cancer Center of the
University of Pennsylvania
Recruiting
IL-12 gene therapy Baylor College of Medicine Completed
ProstAtak™ in patients with localized prostate cancer Advantagene, Inc. Recruiting
Isoflavones in patients with localized prostate cancer Barbara Ann Karmanos Cancer
Institute
Completed
Eflornithine and Bicalutamide Compared With Eflornithine Alone,
Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients
With Localized Prostate Cancer
University of Alabama Completed
Selenomethionine in patients with localized prostate cancer Roswell Park Cancer Center Withdrawn
R-Flubiprofen in patients with high risk localized prostate cancer Myrexis Inc. Unknown
Panobinostat in patients with localized prostate cancer Novartis Pharmaceuticals Completed
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lation of the apoptotic pathway could prove to be benefi-
cial. Gossypol is a natural polyphenol product from
cottonseed that has been shown to be an inhibitor of the
anti-apoptotic molecules, Bcl-2 and Bcl-xL [153,154],
molecules associated with radiation resistance. In conjunc-
tion with radiation, (−)-Gossypol has been reported to en-
hance the induction of apoptosis and inhibit the growth of
PC-3 xenograft tumors [155]. Next, curcumin (diferuloyl-
methane) is a common spice found in Asian cuisine and is
the critical component of turmeric (curcuma longa) [156].
Curcumin exhibits growth inhibitory effects in a broad
range of tumors [157,158]. Furthermore in combination
with radiation, curcumin enhanced both radiation-induced
clonogenic inhibition and apoptosis in prostate cancer cells
[159]. Embelin, a natural compound with pro-apoptotic
effects, e.g., inhibiting X-linked inhibitor of apoptosis
protein (XIAP) while stimulating TNFα and TNF-related
apoptosis-inducing ligand (TRAIL), has been shown to en-
hance the therapeutic efficacy of radiation therapy in PC-3
cells both in vitro and in vivo [160]. Furthermore, Selenite,
another naturally occurring compound, can inhibit cell
growth and induces apoptosis through p53 Ser-15 phos-
phorylation and caspase-mediated pathway in LNCaP cells
[161]. This antiproliferative effect is associated with a de-
crease in the Bcl-2/Bax expression ratio and a decrease in
the ratio of GSH/GSSG (essentially an oxidative state) inLAPC-4 prostate cancer cells. Furthermore, both LAPC-4
and DU145 cells showed increased radiosensitivity when
pre-treated with selenite [162].
Oxidative stress leading to higher levels of reactive oxy-
gen species (ROS) is a common hallmark of cancer cells,
which can stimulate cellular proliferation and cause cellu-
lar injury. Parthenolide, a sesquiterpene lactone derived
from the herbal medicine feverfew, has been reported to
produce a selective radiosensitization in prostate cancer
cells and not effect normal prostate epithelial cells by
activation of NADPH oxidase, which is an important
source of ROS in prostate cancer cells and by suppressing
antioxidants agents. Furthermore, parthenolide decreases
radiation-induced ROS in normal prostate epithelial cells,
suggesting that the intracellular redox status maybe a way
to achieve selective drug targeting [163].
Hypoxia is a feature of many human tumors and has
been implicated as an important biologically modulator of
clinical behavior and treatment response in prostate cancer.
Up-regulation of hypoxia-inducible factor (HIF) signaling
has been reported to be an independent predictor of bio-
chemical failure in prostate cancer patients treat with either
surgery or radiotherapy [164]. Furthermore, a recent study
of 247 patients with localized prostate cancer treated with
high-dose external beam radiation therapy demonstrated
that tumor hypoxia was associated with early biochemical
relapse and local recurrence [165]. Thus an opportunity
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diation treatment in hopes of producing DNA damaging
free radicals.
Clinical trials of radiation sensitization targets
With the deluge of targeted agents over the past decade, it
is rather surprising that limited studies have been reported
with these agents or any agent deemed to sensitize prostatic
tumors to the effects of radiation therapy. Since 2000, only
three such trials have been reported in the English
literature (two using targeted agents, one using natural pro-
ducts). In a phase I/II study by Joensuu et al. daily
administration of 250 mg of gefitinib given concurrently
with three-dimensional conformal radiation therapy for
patients with nonmetastatic prostate cancer was well
tolerated. At a median follow-up of 38 months, 97% of
patient biochemically had no evidence of tumor recurrence
[166]. In a small phase II study of 18 patients with high-risk
prostate cancer, patients were treated with maximum an-
drogen blockade, bevacizumab (10 mg/kg every 2 week
then 15 mg/kg every 3 week for 12 additional weeks) with
concomitant radiation (77.9 Gy delivered by intensity
modulated radiation therapy) to the prostate. The regimen
was well tolerated with no increase in acute toxicities and a
slight increase in late toxicities related to proctitis and cyst-
itis [167]. In a small pilot study reported by Ahmad et al.,
42 patients with prostate cancer were randomly assigned to
receive 200 mg of soy isoflavone or placebo daily for six
months beginning on the first day of radiation therapy.
Total dose of radiation was 77.5 Gy. The authors did not
comment on oncologic outcomes, but it was reported that
the therapy was well tolerated and perhaps lessen adverse
effects seen with radiation therapy [168].
The importance of incorporating novel therapies in
hopes of sensitizing prostatic tumors to radiation is best
illustrated when ADT was combined with radiation ther-
apy. Preclinical studies demonstrated that ADT could in-
duce apoptosis and inhibit angiogenesis in addition to
potentiating the effects of radiation therapy [169]. These
preclinical studies subsequently were translated into a
clinical therapeutic advantage in men with high-risk
localized prostate cancer [170,171]. Fourteen trials using
radiosensitizing agents are in progress or recently com-
pleted (Table 2) in men with high-risk prostate cancer
treated with radiation therapy. A more concerted effort
must be made to bring promising targeted therapeutics to
clinical trial in order to determine treatment efficacy.
Conclusions
Radiation therapy continues to be one of the more popular
treatment options for the definitive treatment of localized
prostate cancer. Recent research has helped understand
and identify maximal tolerated radiation doses needed to
treat prostate cancer. Thus, continuing to increase radiationdoses may not show a clinical benefit and may be fraught
with toxicity. Another way to improve the therapeutic effi-
cacy of radiation is to sensitize the cells to the effects of ra-
diation at current or even lower radiation doses. Different
strategies are being pursued at this time to achieve these
goals. Further development in this field will come as we
gain more understanding of the cellular pathways leading
to radiation resistance and how to best selectively block
these pathways. Though limited clinical trials in prostate
cancer patients support radiosensitizing agents, the field
holds promise and should be aggressively explored further.
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